Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 939 citations · Full text

Medicine, Oncology, Pharmacology +12

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2016 · 514 citations · Full text

Medicine, Nephrology, Oncology +14